MedPath

A Clinical study to evaluate the effect of Hingwadi churna and eranda bhrista haritaki churna along with trivrit taila matra basti in the condition of Primary dysmenorrhea

Phase 2
Not yet recruiting
Conditions
Primary dysmenorrhea. Ayurveda Condition: UDAVARTINI,
Registration Number
CTRI/2025/05/087616
Lead Sponsor
National Institute of Ayurveda
Brief Summary

NEED OF THE STUDY

*Udavarta Yonivyapad* is one of the common Gynaecological disorders, which affects a large section of female population. Conventional allopathic medical treatment may relieve symptoms of dysmenorrhea but it does not address the root cause of the problem. In modern system of medicine dysmenorrhea is treated by hormones, non-steroidal anti-inflammatory, anti-spasmodic, analgesic drugs etc. Long term use of these drugs may cause side effects like hepatotoxicity, nephrotoxicity, headache, dizziness, vertigo, depression, skin rashes etc. So to avoid these complications, an attempt is made to find solution to address root cause of this problem. There is a great scope of research with long lasting effect, to treat the entire feature complex with single regimen and find out the treatment for the underlying pathology from *Ayurveda* for the management of *Udavarta*.

 RATIONALITY OF TRIAL DRUG

The *Hingwadi Churna* contains *Hingu, Sunthi, Maricha, Pippali, Kustha, Yava Kshara*, *Saindhav lavana* as mentioned in *Chakradutta* written by *Shri Chakrapani Dutt* with commentary *Bhavarth Sandipani* by *Shri Jagdishwar Prasad Trpathi, Chaukambha Sanskrit* series office edition 2008, *Chikitsasthan,*chapter 26 on *shloka Chikitsa Adhyaya* , shloka no. 72 , page no. 243*.Pleehashoolaapaham Rajah*.

*Trivrit Taila Matra basti* explained by *Acharya Charak* in *Charak Chikitsa 30 Shloka* no 110 and 111.

*Hingu* is having *Laghu*, *Snigdha*, *Tikshna* Guna, *Katu Rasa, katu Vipaka* and *Ushna Virya*, *Stri-Pushpa* Janana, *Deepana*, *Pachana* properties.

*Shunthi* is *Laghu and Snigdha in Guna, Katu Rasa, Madhura Vipaka* and *Ushna Virya.*It has having *Shula Prashamana*, and *Deepana* properties.

*Kustha* is *Laghu, Ruksha, Tiksna,*

*Yava kshara* is *Tikshna, Laghu, Ruksha*, *Sukshma, Saindhava Lavana* is *Laghu, Snigdha.*

*Matulunga* is *Tikshna* which is used as *Bhavna Dravya* .

*Eranda Bhrista Haritaki churna* has *Eranda* & *Haritaki* as explained *Erandamoola* is *Vrisya Vata Haranam* in *Charaka Sutra 25 shloka* no. 40 .*Haritaki* which is dosha *Anulomani Sarvaroga Prasamni Charaka Chikitsa* 1 *shloka* no.32.

*Pippali* is *Laghu*,*Snigdha*,*Tikshna* in *Guna*, *Katurasa*, *Madhura Vipaka* and *Anushna In virya*.It is considered in *Shula Prashamana Gana* in *Charak Samhita*.

*Maricha* is *Laghu,Teekshna* in Guna, *Katu Rasa*, *Madhura Vipaaka* and *Ushna Virya*. According to *Bhavaprakasha* it has got *Shulaprashamana* and *Deepana* properties.

Hence it is a good combination of *Shula Prashamana* drugs and indicated for *Anuloma Gati* of *Vayu*. In *Udavarta Urdhva Gati* of *Vayu* is causing the pain during menses, this drug thought to be an ideal choice to explore clinically in the management of *Udavarta Yonivyapad*, though there is no direct indication is there for the same.

RESEARCH QUESTIONS:  Is there any difference in the efficacy of Hingwadi Churna and Eranda Bhrista Haritaki Churna along with Trivrit Taila Matra Basti in the management of Udavarta Yonivyapad with special reference to Primary dysmenorrhea?

**HYPOTHESIS:**

**Null hypothesis [H0]:**

There is no difference in the efficacy of *Hingwadi Churna* and *Eranda Bhrista Haritaki Churna* along with *Trivrit Taila Matra Basti* in the management of *Udavarta Yonivyapad* with special reference to Primary dysmenorrhea.

**Alternative Hypothesis [HA]:**

There is difference in the efficacy of *Hingwadi Churna* and *Eranda Bhrista Haritaki Churna* along with *Trivrit Taila Matra Basti* in the management of *Udavarta Yonivyapad* with special reference to Primary dysmenorrhea.

 **AIM:**

To evaluate the efficacy of *Hingwadi Churna* and *Eranda Bhrista Haritaki Churna* along *with Trivrit Taila Matra Basti in* the management of *Udavarta Yoni Vyapada* with special reference to Primary dysmenorrhea

 OBJECTIVE:

Primary objective:

To evaluate and compare the clinical efficacy of Hingvadi Churna and Eranda Bhrista Haritaki Churna along with Trivrit Taila Matra Basti in the management of Udavarta Yoni Vyapada with special reference to Primary dysmenorrhea.

Secondary objective:

i.To assess improvement in the quality of life.

ii.Distribution patterns in Udavarta Yoni Vyapada in different types of prakriti.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
40
Inclusion Criteria

Patients with chief complaint of pain during menses along with associated symptoms Patients who have menstrual pain score more than grade I according to verbal multidimensional scoring system VMSS Patients who had regular menstrual cycles with normal or scanty flow of 26 to 35 days in the last 2 months Patients in age group of 18 to 30 years Patients with H/o using analgesics during menses Patient willing to give voluntary informed consent for the study.

Exclusion Criteria
  • 1.The patient suffering from any severe K/C/O systemic or autoimmune disorders, specially those who are mentioned as Asadhya Vyadhi as per clinical text of Ayurveda will be excluded.
  • 2.Subjects having organic pathology of uterus and adnexa like Fibroid uterus, polyp.
  • 3.Patients with K/C/O anatomical defects of reproductive tract, pelvic inflammatory disease, chronic leucorrhea and thyroid dysfunction, DM.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
NRS – Scale: Numeric Rating Scale for Dysmenorrhea60 days
Secondary Outcome Measures
NameTimeMethod
1. VMSS scale: Verbal Multidimensional Scoring System2. Changes in Quality of life Scale for menstrual disorders

Trial Locations

Locations (1)

NATIONAL INSTITUTE OF AYURVEDA

🇮🇳

Jaipur, RAJASTHAN, India

NATIONAL INSTITUTE OF AYURVEDA
🇮🇳Jaipur, RAJASTHAN, India
DR Rajshree Ganolia
Principal investigator
9530449121
rajshreeganolia3851@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.